Immix Biopharma Future Growth
Future criteria checks 2/6
Immix Biopharma's earnings are forecast to decline at 4.1% per annum while its annual revenue is expected to grow at 72.8% per year. EPS is expected to grow by 19.1% per annum.
Key information
-4.1%
Earnings growth rate
19.1%
EPS growth rate
| Biotechs earnings growth | 27.5% |
| Revenue growth rate | 72.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Aug 12
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2025 | 3 | -20 | N/A | -19 | 2 |
| 12/31/2024 | 1 | -19 | N/A | -17 | 2 |
| 6/30/2024 | N/A | -19 | -15 | -15 | N/A |
| 3/31/2024 | N/A | -18 | -13 | -13 | N/A |
| 12/31/2023 | N/A | -15 | -11 | -11 | N/A |
| 9/30/2023 | N/A | -14 | -13 | -13 | N/A |
| 6/30/2023 | N/A | -11 | -11 | -11 | N/A |
| 3/31/2023 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2022 | N/A | -8 | -7 | -7 | N/A |
| 9/30/2022 | N/A | -27 | -5 | -5 | N/A |
| 6/30/2022 | N/A | -26 | -3 | -3 | N/A |
| 3/31/2022 | N/A | -25 | -3 | -3 | N/A |
| 12/31/2021 | N/A | -24 | -2 | -2 | N/A |
| 9/30/2021 | N/A | -2 | 0 | 0 | N/A |
| 6/30/2021 | N/A | -2 | 0 | 0 | N/A |
| 3/31/2021 | N/A | -2 | 0 | 0 | N/A |
| 12/31/2020 | N/A | -1 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMMX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMMX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMMX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMMX's revenue (72.8% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: IMMX's revenue (72.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMMX's Return on Equity is forecast to be high in 3 years time